DDInter1042 DDInter1070
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
Linagliptin {u} (Compound) resembles {v} (Compound) Alogliptin
Linagliptin {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Linagliptin {u} (Compound) binds {v} (Gene) CYP3A4
Linagliptin {u} (Compound) is included by {v} (Pharmacologic Class) Dipeptidyl Peptidase 4 Inhibitors
Linagliptin {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Linagliptin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Linagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Linagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metamfetamine
Linagliptin {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Linagliptin (Compound) resembles Alogliptin (Compound)
Linagliptin (Compound) treats type 2 diabetes mellitus (Disease)
Linagliptin (Compound) binds CYP3A4 (Gene)
Linagliptin (Compound) is included by Dipeptidyl Peptidase 4 Inhibitors (Pharmacologic Class)
Linagliptin (Compound) causes Upper respiratory tract infection (Side Effect)
Linagliptin may cause a minor interaction that can limit clinical effects when taken with Amcinonide
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine
Linagliptin may lead to a major life threatening interaction when taken with Bexarotene